View Filing Data

Total excluding Corporate TSA revenues [Member]

$ 1,684,399

$ 2,447,827

$ 4,113,270

$ 4,808,095

Corporate TSA revenues [Member]

1,664,329

2,423,959

4,072,058

4,769,597

^[1]

20,070

23,868

41,212

38,498

North America [Member]

North America [Member] | Total excluding Corporate TSA revenues [Member]

1,205,461

1,763,994

2,985,359

3,450,061

North America [Member] | Corporate TSA revenues [Member]

1,205,461

1,762,234

2,985,359

3,447,040

1,760

3,021

International [Member]

International [Member] | Total excluding Corporate TSA revenues [Member]

478,938

683,833

1,127,911

1,358,034

International [Member] | Corporate TSA revenues [Member]

458,868

661,725

1,086,699

1,322,557

Healthcare Distribution [Member] | Total excluding Corporate TSA revenues [Member]

20,070

22,108

41,212

35,477

Healthcare Distribution [Member] | Total excluding Corporate TSA revenues [Member] | Reportable Subsegments [Member]

^[2]

1,559,102

2,298,908

3,834,866

4,528,948

Healthcare Distribution [Member] | North America [Member] | Total excluding Corporate TSA revenues [Member] | Reportable Subsegments [Member]

^[2]

1,559,102

2,298,908

3,834,866

4,528,948

Healthcare Distribution [Member] | International [Member] | Total excluding Corporate TSA revenues [Member] | Reportable Subsegments [Member]

1,112,534

1,653,729

2,778,934

3,239,530

Healthcare Distribution [Member] | Dental [Member] | Total excluding Corporate TSA revenues [Member] | Reportable Subsegments [Member]

446,568

645,179

1,055,932

1,289,418

Healthcare Distribution [Member] | Dental [Member] | North America [Member] | Total excluding Corporate TSA revenues [Member] | Reportable Subsegments [Member]

^[2]

941,292

1,601,350

2,416,368

3,147,730

Healthcare Distribution [Member] | Dental [Member] | International [Member] | Total excluding Corporate TSA revenues [Member] | Reportable Subsegments [Member]

515,946

975,371

1,404,318

1,898,877

Healthcare Distribution [Member] | Medical [Member] | Total excluding Corporate TSA revenues [Member] | Reportable Subsegments [Member]

425,346

625,979

1,012,050

1,248,853

Healthcare Distribution [Member] | Medical [Member] | North America [Member] | Total excluding Corporate TSA revenues [Member] | Reportable Subsegments [Member]

^[2]

617,810

697,558

1,418,498

1,381,218

Healthcare Distribution [Member] | Medical [Member] | International [Member] | Total excluding Corporate TSA revenues [Member] | Reportable Subsegments [Member]

596,588

678,358

1,374,616

1,340,653

Technology [Member] | Total excluding Corporate TSA revenues [Member]

21,222

19,200

43,882

40,565

Technology [Member] | North America [Member] | Total excluding Corporate TSA revenues [Member]

^[3]

105,227

125,051

237,192

240,649

Technology [Member] | International [Member] | Total excluding Corporate TSA revenues [Member]

92,927

108,505

206,425

207,510

Number of reportable segments | segments

$ 12,300

$ 16,546

$ 30,767

$ 33,139

[1]	Corporate TSA revenues represents sales of certain products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which we expect to continue through October 2020.
[2]	Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
[3]	Consists of practice management software and other value-added products, which are distributed primarily to health care providers, and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other services.

Revenue from Contracts with Customers - Contract Balances (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 27, 2020	Dec. 28, 2019
Revenue from Contracts with Customers
Contract with Customer, Liability, Current	$ 57.4	$ 70.8
Contract with Customer, Liability, Noncurrent	6.9	$ 6.2
Contract with Customer, Liability, Revenue Recognized	$ 48.3

Segment Data (Details)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 27, 2020

USD ($)

segments

Jun. 29, 2019

USD ($)

Jun. 27, 2020

USD ($)

segments

Jun. 29, 2019

USD ($)

Segment Data

Total excluding Corporate TSA revenues [Member]

$ 1,684,399

$ 2,447,827

$ 4,113,270

$ 4,808,095

Operating income (loss)

(7,433)

162,288

166,432

334,729

Corporate TSA revenues [Member]

1,664,329

2,423,959

4,072,058

4,769,597

Healthcare Distribution [Member]

^[1]

$ 20,070

23,868

$ 41,212

38,498

Number of countries served globally | segments

Healthcare Distribution [Member] | Total excluding Corporate TSA revenues [Member]

Healthcare Distribution [Member] | Total excluding Corporate TSA revenues [Member] | Reportable Subsegments [Member]

^[2]

$ 1,559,102

2,298,908

$ 3,834,866

4,528,948

Operating income (loss)

^[2]

(25,347)

134,915

122,820

279,439

Healthcare Distribution [Member] | Dental [Member] | Total excluding Corporate TSA revenues [Member] | Reportable Subsegments [Member]

^[2]

1,559,102

2,298,908

3,834,866

4,528,948

Healthcare Distribution [Member] | Medical [Member] | Total excluding Corporate TSA revenues [Member] | Reportable Subsegments [Member]

^[2]

941,292

1,601,350

2,416,368

3,147,730

Technology and Value-Added Services [Member] | Total excluding Corporate TSA revenues [Member]

^[2]

617,810

697,558

1,418,498

1,381,218

^[3]

105,227

125,051

237,192

240,649

Operating income (loss)

$ 17,914

$ 27,373

$ 43,612

$ 55,290

[1]	Corporate TSA revenues represents sales of certain products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which we expect to continue through October 2020.
[2]	Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
[3]	Consists of practice management software and other value-added products, which are distributed primarily to health care providers, and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other services.

Debt - Bank credit lines (Details) - USD ($) $ in Thousands	Jun. 27, 2020	Dec. 28, 2019
Line of Credit Facility [Line Items]
Bank Credit lines	$ 503,178	$ 23,975
Revolving Credit Agreement [Member]
Line of Credit Facility [Line Items]
Bank Credit lines	0	0
364-day credit agreement [Member]
Line of Credit Facility [Line Items]
Bank Credit lines	500,000	0
Other short-term bank credit lines [Member]
Line of Credit Facility [Line Items]
Bank Credit lines	$ 3,178	$ 23,975

Debt - Revolving Credit Agreement, 364-Day Credit Agreement and Other Short-Term Credit Lines Narrative (Details) - USD ($)		4 Months Ended
	Apr. 17, 2020	Apr. 18, 2017	Jun. 27, 2020	Dec. 28, 2019
Line of Credit Facility [Line Items]
Bank credit lines			$ 503,178,000	$ 23,975,000
Revolving Credit Agreement [Member]
Line of Credit Facility [Line Items]
Bank credit lines			0	0
Revolving credit facility maturing in April 2022 [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Initiation Date		Apr. 18, 2017
Revolving credit facility borrowing capacity		$ 750,000,000
Revolving credit facility expiration date		Apr. 30, 2022
Bank credit lines			0.0	0.0
Outstanding letters of credit provided to third parties			9,400,000	9,600,000
Other short-term bank credit lines [Member]
Line of Credit Facility [Line Items]
Bank credit lines			$ 3,178,000	$ 23,975,000
Weighted average interest rate on borrowings under credit lines at period end (in hundredths)			2.86%	3.45%
364-day credit agreement [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Initiation Date	Apr. 17, 2020
Revolving credit facility borrowing capacity	$ 700,000,000
Revolving credit facility expiration date	Apr. 16, 2021
Bank credit lines			$ 500,000,000	$ 0
Weighted average interest rate on borrowings under credit lines at period end (in hundredths)			2.81%
Line of Credit Facility, Expiration Period	364 days
Line of Credit Facility, Current Borrowing Capacity			$ 500,000,000
Line of Credit Facility, Remaining Borrowing Capacity			$ 200,000,000
Line of Credit Facility, Description	The interest rate for borrowings under this facility will fluctuate based on our net leverage ratio. At June 27, 2020, the interest rate on this facility was 2.81%. The proceeds from this facility can be used for working capital requirements and general corporate purposes, including, but not limited to, permitted refinancing of existing indebtedness.

Debt - Long-term Debt (Details) - USD ($) $ in Thousands	6 Months Ended
Debt - Long-term Debt (Details) - USD ($) $ in Thousands	Jun. 27, 2020	Dec. 28, 2019
Debt Instrument [Line Items]
Total long-term debt	$ 625,389	$ 732,757
Less current maturities	(109,587)	(109,849)
Long-term debt	515,802	622,908
Finance lease obligations (See Note 7)	5,918	5,394
Private placement facilities [Member]
Debt Instrument [Line Items]
Total long-term debt	613,469	621,274
U.S. trade accounts receivable securitization [Member]
Debt Instrument [Line Items]
Total long-term debt	0	100,000
Note payable due in 2025 with an interest rate of 3.1% at June 27, 2020
Debt Instrument [Line Items]
Total long-term debt	$ 1,454	0
Borrowing Rate	3.10%
Debt Instrument, Maturity Date, Description	2025
Various collateralized and uncollateralized loans payable with interest in varying installments through 2025 at interest rates ranging from 2.62% to 4.22% at June 27, 2020 and ranging from 2.56% to 10.5% at December 28, 2019 [Member]
Debt Instrument [Line Items]
Total long-term debt	$ 4,548	$ 6,089
Debt Instrument, Maturity Date, Description	2023
Various collateralized and uncollateralized loans payable with interest in varying installments through 2025 at interest rates ranging from 2.62% to 4.22% at June 27, 2020 and ranging from 2.56% to 10.5% at December 28, 2019 [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Borrowing Rate	2.62%	2.56%
Various collateralized and uncollateralized loans payable with interest in varying installments through 2025 at interest rates ranging from 2.62% to 4.22% at June 27, 2020 and ranging from 2.56% to 10.5% at December 28, 2019 [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Borrowing Rate	4.22%	10.50%

Debt - Private Placement Facilities - Narrative (Details) - Private placement facilities [Member] - USD ($)
$ in Millions

1 Months Ended

6 Months Ended

Sep. 15, 2017

Apr. 30, 2020

Jun. 27, 2020

Jun. 23, 2020

Debt instrument, maximum borrowing capacity

$ 1,000

Debt instrument, maturity date

Sep. 15, 2020

Re-financed Debt

Re-financed Debt, Converted Instrument, Issuance Date, Month and Year

2020-04

Re-financed debt, Original Debt, Type of Debt

private placement borrowing

Re-financed debt, Original debt, amount

$ 100

Re-financed debt, Original Debt, Interest Rate of Debt

3.79%

Re-financed debt, Original Debt, Maturity date

Sep. 02, 2020

Re-financed debt, Converted Instrument, Type

similar 10 year borrowing

Re-financed debt, Converted Instrument, Amount

$ 100

Re-financed debt, Converted Instrument, Maturity date

Sep. 02, 2030

Re-financed debt, Converted Instrument, Rate

2.35%

Private placement facilities maturing in September 2020 [Member]

Debt instrument, maturity date

^[1]

Sep. 02, 2020

Minimum [Member]

Term of issuances under private placement facilities

5 years

Maximum [Member]

Term of issuances under private placement facilities

15 years

Average term of issuances under private placement facilities

12 years

[1]	(1) During April 2020, we took certain steps to lock-in a lower interest rate to refinance our $100 million private placement borrowing at 3.79%, coming due on September 2, 2020 with a similar 10 year borrowing at 2.35% maturing on September 2, 2030.

Debt - Private Placement Borrowings (Details) - USD ($)

6 Months Ended

Sep. 15, 2017

Jan. 20, 2016

Jun. 27, 2020

Dec. 28, 2019

Private placement facilities [Member]

Total long-term debt

$ 625,389,000

$ 732,757,000

Less: Deferred debt issuance costs

(817,000)

Total long-term debt

$ 613,469,000

$ 621,274,000

Private placement facilities [Member] | Private placement facilities maturing in September 2020 [Member]

Sep. 15, 2020

^[1]

Sep. 02, 2010

^[1]

$ 100,000,000

^[1]

3.79%

Private placement facilities [Member] | Private placement facilities maturing in January 2022 [Member]

^[1]

Sep. 02, 2020

^[2]

Jan. 20, 2012

^[2]

$ 14,286,000,000

^[2]

3.09%

Private placement facility, frequency of periodic payment

^[2]

Jan. 20, 2022

Annual

Private placement facility annual payment

$ 7,100,000

Debt Instrument, Date of First Required Payment

Jan. 20, 2016

Private placement facilities [Member] | Private placement facilities maturing in January 2024 [Member]

Jan. 20, 2012

$ 50,000,000,000

3.45%

Private placement facilities [Member] | Private placement facilities maturing in December 2024 [Member]

Jan. 20, 2024

Dec. 24, 2012

$ 50,000,000

3.00%

Private placement facilities [Member] | Private placement facilities maturing in June 2021 [Member]

Dec. 24, 2024

Jun. 02, 2014

$ 100,000,000

3.19%

Private placement facilities [Member] | Private Placement facilities maturing in June 2027 [Member]

Jun. 02, 2021

Jun. 16, 2017

$ 100,000,000

3.42%

Private placement facilities [Member] | Private Placement facilities maturing in September 2029 [Member]

Jun. 16, 2027

Sep. 15, 2017

$ 100,000,000

3.52%

Private placement facilities [Member] | Private Placement facilities maturing in January 2028 [Member]

Sep. 15, 2029

Jan. 02, 2018

$ 100,000,000

3.32%